Varicose Vein Treatment: Evidence-Based Options
How chronic venous disease is classified, diagnosed and treated — from compression to endovenous ablation — based on the ESVS 2022 guidelines and peer-reviewed literature.
What are varicose veins?
Varicose veins are dilated, tortuous superficial veins (≥3 mm) of the lower limbs, most commonly caused by reflux — failure of one-way venous valves, usually in the great or small saphenous vein. Persistent reflux produces venous hypertension, which drives symptoms (heaviness, aching, swelling) and, in advanced disease, skin changes and venous ulceration.
Chronic venous disease is among the most common vascular conditions: pooled global prevalence of C2 disease (varicose veins) is approximately 19% of adults, rising to about 21% in Europe, and disease progresses in roughly a third of patients over long-term follow-up.[4] Recognised risk factors include family history, female sex, age, obesity, parity and prolonged standing.[4]
CEAP clinical classification
Disease severity is documented with the CEAP classification (Clinical–Etiological– Anatomical–Pathophysiological); the clinical (C) classes below guide treatment decisions.[1]
| Class | Clinical presentation |
|---|---|
| C0 | No visible or palpable signs of venous disease |
| C1 | Telangiectasias or reticular veins |
| C2 | Varicose veins (≥3 mm diameter) |
| C3 | Oedema |
| C4 | Skin changes: pigmentation, eczema, lipodermatosclerosis |
| C5 | Healed venous ulcer |
| C6 | Active venous ulcer |
Diagnosis: duplex ultrasound first
Duplex ultrasound of the lower limbs is the recommended first-line investigation (Class I) for suspected chronic venous disease: it maps reflux (>0.5 s of retrograde flow), measures vein diameters and confirms deep-system patency — all of which determine which treatment options are anatomically appropriate.[1]
Treatment options, graded
Recommendation classes below refer to the ESVS 2022 guidelines for great saphenous vein incompetence.[1] Treatment selection is individualised by a vascular specialist.
Compression therapy
Class I · Level B (symptoms/oedema)Elastic compression stockings exerting ≥15 mmHg at the ankle reduce venous symptoms; 20–40 mmHg compression reduces oedema. Compression manages symptoms but does not correct underlying reflux.
Endovenous thermal ablation (EVLA / RFA)
Class I · Level A (GSV, first choice)Laser or radiofrequency energy closes the vein thermally. Requires tumescent anaesthesia along the treated segment to protect surrounding tissue; nerve injury and skin burns are recognised but uncommon risks.
Cyanoacrylate adhesive closure (CAC)
Class IIa · Level A (when NTNT preferred)A medical-grade adhesive seals the vein without heat or tumescent anaesthesia. Randomised and cohort data show occlusion rates comparable to thermal ablation with less peri-procedural pain. VenaBlock® belongs to this class.
Mechanochemical ablation (MOCA)
Class IIb · Level ACombines mechanical endothelial disruption with liquid sclerosant. A non-thermal option; long-term occlusion rates in trials are somewhat lower than thermal ablation.
Ultrasound-guided foam sclerotherapy
Adjunct / selected casesFoam sclerosant injected under ultrasound guidance. Useful for tributaries and recurrences; truncal occlusion durability is lower than ablation, so it is not first-line for saphenous trunks.
High ligation & stripping (surgery)
Class IIa · Level A (if endovenous unavailable)Open surgical removal of the saphenous vein under anaesthesia. Effective, but with longer recovery and more wound-related morbidity than endovenous options; reserved for settings where ablation is not available or not anatomically feasible.
Where VenaBlock® fits
VenaBlock® is a cyanoacrylate adhesive closure system developed by INVAMED. Within the guideline framework above, it addresses the non-thermal, non-tumescent treatment pathway: closure of the incompetent saphenous trunk with a single access puncture, local anaesthetic at the access site only, and no thermal-injury risk by design.
Its published evidence base includes a 538-patient great saphenous vein cohort with 99.4% Kaplan–Meier occlusion at 12 months[2] and the prospective RIVIERA trial (Singapore General Hospital), which reported 97.2% occlusion at 6 months with a mean device time of 23.4 minutes and significant quality-of-life improvements.[3]
Frequently asked questions
What is the most effective treatment for varicose veins?+
No single treatment is best for every patient. Current European guidelines (ESVS 2022) recommend endovenous ablation as the first-choice treatment for great saphenous vein incompetence, in preference to open surgery and foam sclerotherapy. Within ablation, thermal techniques (laser, radiofrequency) and non-thermal techniques (including cyanoacrylate adhesive closure, Class IIa/Level A) achieve broadly comparable occlusion rates; the choice depends on anatomy, comorbidity, patient preference and physician experience.
What is cyanoacrylate adhesive closure (vein glue)?+
Cyanoacrylate adhesive closure (CAC) is a non-thermal, non-tumescent endovenous technique that seals the incompetent saphenous vein with a medical-grade cyanoacrylate adhesive delivered through a catheter under ultrasound guidance. Because no heat is used, tumescent anaesthesia along the vein is not required. VenaBlock® is a CAC system documented in peer-reviewed studies including a 538-patient cohort (99.4% occlusion at 12 months) and the prospective RIVIERA trial.
Do varicose veins need treatment, or can they be managed conservatively?+
Compression stockings reduce symptoms and oedema and are recommended for symptomatic chronic venous disease. However, compression does not correct the underlying reflux. For patients who are candidates for saphenous ablation, guidelines favour definitive endovenous treatment over long-term compression alone. Asymptomatic C1 disease (spider veins) does not generally require intervention on medical grounds.
Is varicose vein treatment painful?+
Thermal ablation requires tumescent anaesthesia — a series of injections along the treated vein. Non-thermal techniques such as cyanoacrylate closure use local anaesthetic at the access site only. In randomised data comparing CAC with thermal ablation, peri-procedural pain scores were lower with CAC; individual experience varies.
How successful is endovenous treatment long term?+
Published series report 12-month truncal occlusion rates of roughly 92–99% for both thermal ablation and cyanoacrylate closure. For VenaBlock® specifically, a 538-patient cohort reported 99.4% Kaplan–Meier occlusion at 12 months, and the RIVIERA prospective trial reported 97.2% at 6 months. Recurrence of varicose disease over years can occur with any modality as venous disease progresses.
What are the risks of cyanoacrylate vein closure?+
Reported adverse events include phlebitis-like inflammatory reactions, puncture-site infection, and hypersensitivity to cyanoacrylate (approximately 6–7% in pooled guideline data). Serious events such as deep vein thrombosis are uncommon in published series. A vascular specialist will screen for contraindications, including known cyanoacrylate allergy and acute thrombosis.
References
- De Maeseneer MG, Kakkos SK, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. DOI: 10.1016/j.ejvs.2021.12.024
- Eroglu E, et al. A new n-butyl-2-cyanoacrylate glue ablation catheter with application guiding light for venous insufficiency: twelve-month results. Vascular. 2018;26(5):547–555. DOI: 10.1177/1708538118770548
- Linn YL, Yap CJQ, Soon SXY, et al. Six months results of the RIVIERA trial. Phlebology. 2021;36(10):816–826. DOI: 10.1177/02683555211025181
- Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976.
Medical disclaimer: This overview is educational and does not constitute medical advice, diagnosis or a treatment recommendation. Treatment decisions should be made with a qualified vascular specialist after duplex ultrasound assessment. venablock.com is operated by INVAMED, the manufacturer of VenaBlock®; content is compiled from peer-reviewed literature and current guidelines, with sources cited above.